The Science Foundation Ireland Research Centre for Pharmaceuticals
Research
Our world-leading research programme is defined through its unique collaboration abilities and building R&D excellence in one of Ireland’s largest industries. SSPC has a broad research capability that encompasses scientific expertise in small and large molecule drug substance and drug product manufacturing with a particular emphasis on process optimisation, data analytics and ATMPs.
Talent
SSPC nurtures a talent pipeline of high calibre scientists and engineers for the sector, through our internal PhD training programme and various CPD mechanisms available to our industry partners. SSPC offers a unique proposition through its industry placement programme and 65% of SSPC graduates go on to be employed in industry both nationally and globally.
Industry
Since its inception, SSPC has successfully collaborated with over 46 industry partners, composed of indigenous and foreign operations, whose size range from small to multi-national. Collectively, this demonstrates a strong track-record in delivering applied research that enables industry to solve challenges leading to the development of better medicine. SSPC are developing innovative technologies to address key challenges facing the pharmaceutical and biopharmaceutical industry.
Latest News
Join SSPC's Alumni Group
SSPC alumni can be found all over the world, no matter how long you were part of our Centre, we want to connect and would love to hear from you.
SSPC’s world-leading Research Programme
Our unique and innovative culture of collaboration is helping the global pharmaceutical and biopharmaceutical industry to develop more environmentally sustainable methods for drug manufacturing; to increase the range of medicines available to the public and to reduce drug manufacturing costs. SSPC’s advanced research programme extends from Molecule, Materials and Medicine into the Manufacturing and Modelling space.
These themes focus on developing new methodologies for the asymmetric synthesis of APIs, molecules & methods for automated & in-flow generation of targeted drug hybrids & new therapeutic agents.
Advancing the understanding of single-component crystalline materials (SCCMs) and, especially, multi-component crystalline materials (MCCMs) in order to enable improved orally delivered drug products.
Optimising the development, production & use of safe, effective medicines with focus on poorly soluble drugs, personalized, age appropriate medicines & rational formulation approaches with predictive performance.
Enabling a disruptive change in manufacture of drug substances & drug products, through the development & implementation of continuous manufacturing, flow chemistry & end-to-end manufacturing methodologies.
This theme will develop new techniques to design and predict behaviour in silico in order to reduce trial-and-error experimentation. Developing new transformative physical models for broad uptake in drug manufacture.
